Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1972 1
1975 1
1976 1
1977 1
1978 1
1979 2
1980 1
1982 1
1983 1
1985 1
1986 2
1988 1
1992 1
1993 1
1994 1
1995 1
1996 2
1997 6
1998 4
1999 8
2000 5
2001 4
2002 6
2003 5
2004 2
2005 4
2006 5
2007 11
2008 2
2009 8
2010 2
2011 4
2012 2
2013 6
2014 8
2015 4
2016 4
2017 8
2018 3
2019 7
2020 6
2021 8
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

146 results
Results by year
Filters applied: . Clear all
Page 1
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Among authors: sills g. Lancet. 2021 Apr 10;397(10282):1375-1386. doi: 10.1016/S0140-6736(21)00246-4. Lancet. 2021. PMID: 33838758 Free PMC article. Clinical Trial.
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Among authors: sills g. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.
Walker LE, Frigerio F, Ravizza T, Ricci E, Tse K, Jenkins RE, Sills GJ, Jorgensen A, Porcu L, Thippeswamy T, Alapirtti T, Peltola J, Brodie MJ, Park BK, Marson AG, Antoine DJ, Vezzani A, Pirmohamed M. Walker LE, et al. Among authors: sills gj. J Clin Invest. 2019 Apr 8;129(5):2166. doi: 10.1172/JCI129285. eCollection 2019 Apr 8. J Clin Invest. 2019. PMID: 30958803 Free PMC article. No abstract available.
Sulthiame monotherapy for epilepsy.
Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Milburn-McNulty P, et al. Among authors: sills gj. Cochrane Database Syst Rev. 2014 Mar 9;2014(3):CD010062. doi: 10.1002/14651858.CD010062.pub2. Cochrane Database Syst Rev. 2014. PMID: 24609897 Free PMC article. Updated. Review.
Combining antiepileptic drugs--rational polytherapy?
Brodie MJ, Sills GJ. Brodie MJ, et al. Among authors: sills gj. Seizure. 2011 Jun;20(5):369-75. doi: 10.1016/j.seizure.2011.01.004. Epub 2011 Feb 8. Seizure. 2011. PMID: 21306922 Free article. Review.
Sulthiame add-on therapy for epilepsy.
Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Milburn-McNulty P, et al. Among authors: sills gj. Cochrane Database Syst Rev. 2015 Oct 28;(10):CD009472. doi: 10.1002/14651858.CD009472.pub3. Cochrane Database Syst Rev. 2015. PMID: 26510094 Updated. Review.
146 results